A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)
Status:
Completed
Trial end date:
2002-07-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, open label, randomized, controlled, safety trial in subjects aged
6-75 years with a diagnosis of moderate to severe, persistent asthma. A total of 1899
subjects were randomized (2:1) to either the active treatment group or the control group.
Upon successful completion of the screening period (~2 weeks), each subject entered the 24
week study.